

New York State Delays Medication-Assisted Treatment Formulary Change

MVP Health Care® (MVP) has been informed by the New York State Department of Health (NYSDOH) that the implementation of the Medication-Assisted Treatment (MAT) formulary change for Managed Care Medicaid Members has been delayed until April 1, 2021. This update was originally communicated to Members and Providers in October with an original effective date of November 1, 2020.

On April 1, 2021, this change will require that *brand* name Suboxone films be a preferred tier 1 medication. The generic Suboxone films (buprenorphine/naloxone) will be excluded. This change will affect the MVP Medicaid formulary only.

Currently, the MVP Medicaid formulary covers *generic* Suboxone films (buprenorphine-naloxone) at tier 1. Brand Suboxone is non-formulary and coverage is subject to prior authorization. These medications are subject to utilization management edits that MVP has in place to ensure appropriate utilization, including quantity limits.

MVP will continue to work with the NYSDOH for additional updates and guidance to understand the implications for our Members and Providers.

To view a summary of all updates, visit mvphealthcare.com/Providers.

To receive future FastFax messages by email, send a request to MVPFastFax@mvphealthcare.com.

Questions? Contact your MVP Professional Relations Representative or call the MVP Customer Care Center for Provider Services at 1-800-684-9286.

